Business
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing GlobeNewswire August 21, 2024 SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today anno
GlobeNewswire
August 21, 2024
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx technology involves tethering a therapeutic to hydrogel microspheres via linkers with tunable, pre-programmed release rates. Semaglutide is a peptide GLP-1 agonist that is the active ingredient in the Novo Nordisk blockbuster drugs Ozempic® and Wegovy®; Ozempic® is used to treat Type 2 diabetes, whereas Wegovy® is a higher-dose version approved for weight loss. Combined sales of these drugs reached about $20 billion in 2023, and demand exceeded supply.
